Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment

Inclusion Criteria: * Histologically or cytologically proven diagnosis of malignant mesothelioma * Man or woman 21 years and above * Adequate performance status (ECOG 0, 1, or 2) * Patient must have adequate organ function as the following: * Absolute neutrophils counts (ANS) \> 2500/μL. * Platelets \> 150,000/μL. * Hemoglobin \> 10 g/dL. * Total Bilirubin \< 1.5 Upper Normal Limit (UNL). * Alanine aminotransferase (ALT), AST (aspartate aminotransferase)and alkaline phosphatase must be \< 1.5 times of the upper limit of normal. * LDH (lactate dehydrogenase) \< 500 int. unit/L * Estimated GFR (glomerular filtration rate) \> 45 ml/min. * Written informed consent * Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation. * Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy. Exclusion Criteria: * Evidence of liver metastasis * Any bone involvement * Prior radiotherapy, cytotoxic or biologic systemic treatment * Any history of Asthma or COPD (chronic obstructive pulmonary disease) that needs systemic therapy with steroids for more than 2 weeks during the last 2 years. * Treatment with systemic steroids for more then 1 month during the last year. * Active smokers that are unable to quite smoking * Any treatment with investigational agent within 30 days prior to registration for protocol therapy. * Cerebrovascular accident, transient ischemic attack or myocardial infarction within 6 months prior to registration for protocol therapy. * Evidence of pulmonary embolism within 6 months prior to registration for protocol therapy. * Any history of solid or hematologic malignancies. * Patient with positive HIV serology at screening. * Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study. * Uncontrolled hypertension (\> 150/100 mm Hg despite optimal medical therapy). * Evidence of ongoing cardiac dysrhythmias of NCI CTCAE (Common Toxicity Criteria for Adverse Effects) Version 3.0 grade 2. * Patients in whom radiation or surgery is indicated * Significant swallowing disorders. * Small bowel surgery. * Suspicion of absorption disruption as a result of abdominal radiation * Pre-existing malabsorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption. * Evidence of concurrent (\< 5 years) second malignancy * Mental disorders. * Inability to give written informed consent.